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Abstract: Dendritic cells (DCs) are essential in order to
combat invading viruses and trigger antiviral responses.
Paradoxically, in the case of HIV-1, DCs might contribute
to viral pathogenesis through trans-infection, a mecha-
nism that promotes viral capture and transmission to
target cells, especially after DC maturation. In this review,
we highlight recent evidence identifying sialyllactose-
containing gangliosides in the viral membrane and the
cellular lectin Siglec-1 as critical determinants for HIV-1
capture and storage by mature DCs and for DC-mediated
trans-infection of T cells. In contrast, DC-SIGN, long
considered to be the main receptor for DC capture of
HIV-1, plays a minor role in mature DC-mediated HIV-1
capture and trans-infection.
Introduction
Dendritic cells (DCs) are derived from bone marrow precursors
and have a major role in antigen presentation and induction of
host immune responses. DCs express a plethora of pathogen
recognition receptors, such as toll-like receptors, scavenger
receptors, and lectin receptors, which recognize evolutionarily
conserved pathogen-associated molecular patterns and contribute
to antimicrobial defense. Upon infection, pathogen sensing by
immature DCs (iDCs) in mucosal tissues elicits the secretion of
cytokines and chemokines. This early innate response creates an
inflammatory microenvironment that prompts DC maturation
and migration to secondary lymphoid tissues. Concurrently, co-
stimulatory molecules are expressed on the cell membrane,
preparing DCs for competent T cell priming. In the T cell areas
of the lymph node, fully mature DCs (mDCs) present pathogen-
derived antigens to T lymphocytes. By these means, DCs
coordinate innate and adaptive immune responses against
invading pathogens and thus have a critical role in limiting viral
infections [1–3]. In the course of the HIV-1 infection, however,
the contribution of DCs to the antiviral state could be confounded
by their ability to facilitate HIV-1 transmission to bystander CD4+
T cells and promote viral spread.
Since DCs express the HIV receptor CD4 and viral coreceptors
on their surface [4,5], they are expected to be infected by HIV-1.
In cell culture, however, the percentage of HIV-1-infected DCs is
always much lower than for activated CD4+ T cells [6–9] or
macrophages. Moreover, large amounts of HIV-1 are required to
successfully infect DCs. DC maturation further limits infection:
mDCs are 10-fold to 100-fold less susceptible to HIV-1 than iDCs
[6,10,11]. Thus, although the most important DC subsets are
susceptible to HIV-1 infection [12–15], this seems to be a rare
event. HIV-1 infection of DCs also appears to be uncommon in
vivo, although it has been reported for both cutaneous and
mucosal DCs [9,16]. The identification of the host restriction
factor SAMHD1 (sterile alpha motif domain– and HD domain–
containing protein 1) helped to explain the limited HIV-1 infection
of DCs [17,18]. SAMHD1 restricts infection by reducing the
nucleotide pool available for reverse transcription, thereby limiting
replication of the viral genome [19].
In contrast to HIV-1, HIV-2 naturally infects DCs [20], and this
function depends on counteraction of SAMHD1 by Vpx, a viral
protein not present in HIV-1 [17,18]. Vpx is incorporated into
HIV-2 particles and is released after viral fusion, inducing
degradation of host cell SAMHD1. However, efficient DC
infection is not required for disease progression, since HIV-1 is
much more pathogenic than HIV-2. This discrepancy might be
explained by differences in innate sensing. HIV-2 genome
replication in infected DCs is detected by the innate sensor cGAS,
a cyclic guanosine or adenosine monophosphate synthase that
recognizes viral DNA and triggers immune responses [20,21],
while SAMHD1-mediated restriction of HIV-1 prevents cytoplas-
mic cDNA synthesis and consequently precludes induction of
antiviral type I interferon responses [20].
Despite low rates of infection by HIV-1, DCs can efficiently
capture HIV-1 and mediate potent viral transmission, thus
promoting a vigorous infection of CD4+ T cells [11] in the
absence of productive DC infection [22] or innate immune
detection. This so-called trans-infection is particularly robust for
mDCs [6,23,24] and takes place at viral concentrations that do not
allow for efficient infection of CD4+ T cells by cell-free virus [25].
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HIV-1 trans-infection involves capture and internalization of intact
virions by DCs, trafficking of trapped viruses without membrane
fusion, and finally release of infectious virions towards contacting
CD4+ T cells [25,26].
Based on their ability to retain virions and travel to lymphoid
tissues, it was initially proposed that iDCs act as ‘‘Trojan horses,’’
capturing HIV-1 in the mucosa and then migrating to secondary
lymphoid tissues, where stored HIV-1 could be transmitted to
CD4+ T cells and contribute to the spread of infection [25,27].
However, the capacity of iDCs to function as ‘‘Trojan horses’’ is
limited: iDCs quickly degrade most of the incoming virions, and
trans-infection by iDCs is thus only possible in the hours that follow
a viral encounter [28]. By contrast, viral capture is potently
enhanced in mDCs [29,30], and infectious HIV-1 is stored in an
apparently intracellular compartment in these cells. Storage has
been reported to occur in a nonclassical endosomal compartment
enriched in tetraspanins [31] or at an invagination of the plasma
membrane that is distinct from endocytic vesicles [32]. In this
compartment, HIV-1 is expected to be protected from endosomal
or cytosolic degradation pathways [26]. The precise nature and
origin of the capture and storage compartment is currently
unknown, and it is also not clear whether it is constitutive or virus
induced. An interesting parallel exists with the budding compart-
ment in HIV-infected macrophages, which constitutes an invag-
ination of the plasma membrane that can be rapidly shifted to a T
cell contact zone, thus facilitating cell-to-cell transfer of HIV-1
[33,34]. Kinetic analysis suggests that the HIV-1 capture and
storage compartment in mDCs gradually connects with the
extracellular milieu and is constantly remodeled [35], which may
favor both viral accumulation and subsequent transfer.
HIV-1 transmission has been suggested to occur primarily at a
zone of cell-to-cell contact—the infectious synapse—that resem-
bles the immunological synapse, a spatially segregated supramo-
lecular structure formed by T cells to recognize antigens presented
by DCs [36]. Upon contact with mDCs, the HIV entry receptors
CD4, CCR5, and CXCR4 on CD4+ T cells are concentrated in
the contact zone [24], thus providing optimal conditions for viral
entry. The virus storage compartment in DCs is shifted towards this
contact zone, facilitating rapid and efficient infection of the
neighboring T cell [24,31,37,38]. Although trans-infection via
mDCs does not involve new virus production from DCs, this
transfer mode appears to be highly related to the virological synapse
established between HIV-1 infected cells and target cells [38].
Trans-infection of CD4+ T cells by HIV-1 captured on mDCs
appears to be a particularly potent mechanism of viral transmis-
sion and is thus thought to play a major role in HIV-1 spread in
lymphoid tissues in vivo. Thus, the capacity of mDCs to capture
HIV-1 for trans-infection while being largely resistant to HIV-1
infection may be an important aspect of HIV-1 pathogenesis. In
this review, we will focus on the role of recently identified viral and
cellular factors involved in HIV-1 capture by mDCs and discuss
how they might contribute to HIV-1 immune escape and
pathogenesis.
HIV-1 Trans-Infection by mDCs: No Sign of DC-
SIGN
The dendritic cell-specific intercellular adhesion molecule-3
(ICAM)–grabbing non-integrin (DC-SIGN) has previously been
suggested to be the main capture receptor for HIV-1 on DCs
[25,27]. DC-SIGN is a C-type lectin receptor expressed
abundantly on the surface of iDCs that interacts with the HIV
surface glycoprotein gp120 [25,39] and thus acts as a capture
receptor for HIV-1 on iDCs (Figure 1A). The affinity of gp120 for
DC-SIGN is five times greater than for its cognate receptor CD4
[39], suggesting that DC-SIGN on iDCs could be of particular
importance when only few HIV-1 particles are present, such as in
early infection [25]. This observation led to the ‘‘Trojan horse’’
hypothesis, which argues that DC-SIGN captures HIV-1 in the
mucosa and facilitates its transport to secondary lymphoid organs
rich in CD4+ T cells that can be efficiently trans-infected [25].
However, the restricted capacity of iDCs to sustain trans-infection
[28,40] and the limited contribution of DC-SIGN to viral
transmission reported in several independent studies [29,30,41–
47] argued against the original ‘‘Trojan horse’’ hypothesis.
In contrast to iDCs, mDCs located in lymphoid tissues can
effectively transfer HIV-1 to T cells. Cell-associated transfer via
the virological synapse is believed to constitute the major mode of
transmission in the densely populated lymphoid tissue. The
continuous interaction between mDCs and CD4+ T cells [48]
could be particularly relevant to this tissue, allowing for infectious
synapse formation. However, DC-SIGN expression is reduced
upon DC maturation [25,49,50], while HIV-1 capture and trans-
infection are potently enhanced [23,24,29,30]. DC-SIGN blocking
agents such as mannan or anti-DC-SIGN antibodies have minimal
effects on capture and transfer of HIV-1 by mDCs, while they
completely abrogate viral capture and transfer in DC-SIGN-
transfected cell lines [29,30]. Furthermore, DC-SIGN is not
expressed on the surface of blood myeloid DCs and Langerhans
cells [5,51], while these cells efficiently capture and trans-infect
HIV-1, especially after maturation [29,52].
These observations indicate that DC-SIGN is dispensable for
HIV-1 capture by mDCs and suggest that this process is
mediated by other cell-surface molecules. This hypothesis is
strongly supported by the finding that HIV-1 capture by mDCs
does not require the viral envelope glycoproteins [29,53], while
DC-SIGN interaction with HIV-1 occurs via gp120 [25].
Mature DCs and blood myeloid DCs capture HIV-1 particles
lacking viral envelope glycoproteins as efficiently as wild-type
virus, thus excluding gp120-interacting molecules as essential
binding receptors [29]. Other HIV-1 receptors described on
DCs, including CD4, several C-type lectins (e.g., mannose-
binding receptor, dendritic cell immunoreceptor (DCIR), and
trypsin-sensitive receptors), and glycosphingolipids (e.g., galac-
tosyl-ceramide) also bind to the envelope glycoproteins [29,41–
47] and are therefore also excluded as receptors for capture of
particles lacking viral envelope proteins. These combined results
indicate that another surface receptor must be responsible for
HIV-1 capture and transmission by mDCs and that this
receptor should recognize viral membrane constituents other
than the HIV-1 envelope glycoprotein.
Bitter-Sweet Attraction between HIV-1 and mDCs
Since the viral envelope glycoproteins are dispensable for mDC
capture, other constituents of the viral membrane should be
responsible. These molecules could be proteins, lipids, or sugars
but should be widely distributed, because HIV-1 capture by mDCs
is independent of the producer cell type [29,53]. Recognition
molecules should also be present in the membrane of cellular
microvesicles (e.g., exosomes), which undergo capture by mDCs
similar to HIV-1 [54]. Both exosomes and HIV-1 appear to bud
from cholesterol-enriched microdomains in the T cell plasma
membrane [55–57] and share glycosphingolipids and various
membrane proteins that reside in lipid rafts. Capture and transfer
of HIV-1 by mDCs converges with the exosome trafficking
pathway and HIV-1 and exosomes compete for mDC capture,
indicating that they utilize the same pathway [54].
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Internalization of HIV-1 or exosomes is not abrogated by
pretreatment of these particles with proteases; therefore, capture
appears to be independent of membrane proteins. In contrast,
modifying the lipid composition by specific lipid biosynthesis
inhibitors in producer cells affects particle capture by mDCs
without altering particle release [53,54]. Specifically, treatment
of HIV-1- or exosome-producing cells with inhibitors of
glycosphingolipid biosynthesis yielded particles with reduced
glycosphingolipid content, which exhibited reduced capture by
mDCs [53,54]. These findings suggested a critical role of
glycosphingolipids for mDC capture and storage of HIV-1 and
exosomes [54].
If capture by mDCs is mediated by the particle’s lipid
composition and independent of membrane proteins, this property
should also be observed for liposomes that have the size and lipid
composition of HIV-1 but lack any protein. This is indeed the
case: liposomes mimicking the lipid composition of HIV-1 were
efficiently recognized by mDCs and competed with HIV-1 for
mDC capture [58,59]. Gangliosides represent the predominant
group of membrane glycosphingolipids, and mDC capture showed
complete ganglioside dependence when comparing liposomes
containing or lacking gangliosides. Furthermore, ganglioside-
containing liposomes trafficked to the same compartment as
HIV-1 and exosomes, and these particles competed with each
other for mDC capture [54,58].
All gangliosides are composed of a ceramide molecule and a
variety of sialylated carbohydrate head groups (Figure 1B).
Liposomes containing only ceramide were not captured by mDCs,
suggesting that the sialylated carbohydrate head group constitutes
the molecular recognition domain. Sialic acid on cellular
membrane molecules has been identified as an attachment
receptor for several pathogens and toxins [60–64]. It therefore
appeared to be a good candidate for a potential mDC recognition
moiety. Removing sialic acid from the membrane of liposomes or
viruses by neuraminidase treatment or reconstituting liposomes
with asialo-gangliosides abolished capture by mDCs, indicating
that sialic acid is necessary for mDC recognition, though not
sufficient. No capture was observed for particles containing GM4,
the simplest ganglioside (Figure 1B), while mDC capture was
efficient when the membrane contained GM1, GM2, or GM3.
GM4 has its sialic acid moiety bound to a single galactose, while
GM3, the next ganglioside in complexity, as well as GM1 and
GM2 carries sialic acid bound to lactose as a head group. This
sialyllactose head group (Figure 1B) therefore appears to constitute
the molecular determinant for mDC recognition [58]. According-
ly, soluble sialyllactose efficiently prevented HIV-1 capture by
mDCs when added at high concentrations. However, efficient
particle capture requires membrane gangliosides, and attachment
of sialyllactose to ceramide is probably needed for a higher binding
avidity. The hydrophilic moiety of ceramide in the membrane
Figure 1. HIV-1 binding to DC receptors. A. HIV-1 can bind to DC-SIGN via recognition of the viral envelope glycoprotein. B. Several
gangliosides in the HIV-1 lipid membrane expose a sialyllactose moiety, while GM4 only carries sialic acid on galactose. C. Siglec-1 can capture HIV-1
through recognition of sialyllactose moieties of viral membrane gangliosides. Abbreviations: Cer (ceramide), Gal (galactose), GalNAc (N-
acetylgalactosamine), Glu (glucose), SiA (sialic acid).
doi:10.1371/journal.ppat.1004146.g001
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interface may be part of the recognition domain, either increasing
the binding affinity or orienting the sialyllactose group upon
hydrophobic interaction between ceramide and other membrane
constituents. Both GM1 and GM3 can serve as mDC recognition
molecules when incorporated at high concentrations, while GM3
appears to be more efficient at limiting ganglioside concentrations.
Accordingly, knockdown of GM3 (but not GM1) from HIV-1
producer cells and hence from virions strongly reduced capture by
mDCs [59].
Siglec-1 (CD169) Is the Capture Receptor for HIV-1
on mDCs
The observation that the sialyllactose moiety of viral membrane
gangliosides is recognized upon HIV-1 capture by mDCs
suggested that the attachment receptor may be a sialic-acid-
binding cell-surface molecule. Obvious candidates were the family
of sialic-acid-binding immunoglobulin-like lectins (Siglecs): these
type I transmembrane proteins carry an amino-terminal V-set
domain that directly interacts with sialylated ligands, mediating
both cellular interactions and immune responses [65]. Using
transcriptome analysis, SIGLEC1 gene (coding for Siglec-1,
CD169, or Sialoadhesin) was identified as the only member of
the Siglec family that was significantly up-regulated upon DC
maturation with lipopolysaccharide (LPS) [66]. Since this treat-
ment had been shown to strongly enhance the capture capacity of
mDCs for HIV-1, Siglec-1 was considered a prime candidate for a
capture receptor. Similar results were observed upon type I
interferon treatment of mDCs, which enhanced both Siglec-1
surface expression and HIV-1 capture [67].
Several lines of evidence demonstrated that Siglec-1 expression
correlates with the HIV-1 capture and trans-infection capacity of
primary DCs [66,67]. Specific antibodies against Siglec-1 inhibited
HIV-1 capture in a dose-dependent manner. In addition, Siglec-1
knockdown by small interfering RNA (siRNA) strongly reduced
viral capture and trans-infection, while de novo expression of
Siglec-1 in cells devoid of this receptor enhanced viral capture and
trans-infection. Hence, Siglec-1 was identified as a novel DC
receptor for HIV-1 capture and trans-infection (Figure 1C), which
is highly up-regulated in blood myeloid DCs exposed to LPS or
type I interferon [66,67]. In contrast, other members of the Siglec
family (i.e., Siglec-5 or Siglec-7) had no effect in these assays
despite their capacity to bind sialic acid.
Induction of Siglec-1 expression upon LPS or interferon
treatment explains why mDCs are able to capture higher amounts
of HIV-1 than iDCs and why this process does not require the
viral surface glycoprotein but relies on viral membrane ganglio-
sides (Figure 1C). Siglec-1 recognition has been previously
Figure 2. Trans and cis recognition of Siglec-1 ligands. A. Siglec-1 has 16 C2-type domains that extend the V-set domain from the glycocalix of
the cell, allowing for recognition of sialylated molecules on different ligands and pathogens such as HIV-1. B. Other members of the Siglec family
display a lower number of C2-type domains and interact only in cis, with sialylated molecules exposed on the membrane of the same cell.
doi:10.1371/journal.ppat.1004146.g002
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suggested to play a role in enhancing macrophage infection by
HIV-1 [68], but this study reported a Siglec-1 interaction with
sialylated viral envelope proteins and not with membrane
gangliosides. This enhancing effect is likely due to increased viral
capture and thus prolonged exposure to the cell-surface receptors
CD4 and CCR5 on the macrophage surface. Future experiments
should define whether macrophage capture of HIV-1 requires
sialylated viral envelope glycoproteins or depends on recognition
of membrane gangliosides as observed for mDCs.
Although all Siglecs have the potential to interact with sialylated
gangliosides through their respective V-set domains, several
distinctive features help to explain why Siglec-1 is the only family
member that effectively mediates HIV-1 capture [66,67,69].
Siglec-1 is the largest member of the family, containing 16 Ig-
like C2-type extracellular domains [70]. These domains separate
the ligand-binding site from the cell surface, extending the V-set
domain beyond the glycocalix of the cell (Figure 2). Thus, Siglec-1
is available for interaction with external ligands, while shorter
Siglecs mainly bind cell-surface molecules in cis [65], masking their
potential HIV-1 binding capacity (Figure 2). Siglec-1 constructs
containing less than six Ig-like C2-type domains are unable to
mediate sialic-acid-dependent binding in trans unless the cells are
treated with sialidases to remove their own cell-surface sialic acids
[71].
The affinity of Siglec-1 for sialylated ligands is in the
micromolar range, but high-avidity binding can be achieved upon
receptor and ligand clustering [65]. Live-cell imaging of viral
capture by mDCs shows that viruses rapidly bind over the entire
plasma membrane but subsequently traffic towards one pole of the
cell, where they gradually accumulate and cluster [35]. Lipidomic
analysis of HIV-1 membranes estimated that there are 12,000
GM3 molecules per virion [72,73]. Other gangliosides such as
GM1 are also present in HIV-1 membranes [58] but remain to
be quantified. The presence of thousands of sialyllactose-
containing gangliosides in the viral membrane is expected to
support high-avidity interactions with the host-cell plasma
membrane. These multiple interactions should yield stable viral
attachment despite the relatively poor affinity of each individual
interaction; the binding strength may thus be superior to that
achieved by the higher affinity interaction of DC-SIGN or the
viral CD4 receptor with only 1467 envelope trimers per virion
[74].
Siglec-1 Role as a Pathogen Recognition Receptor
Siglec-1 binds promiscuously to many sialylated molecules
typically found on pathogens, with a preference for N-Acetylneur-
aminic acid (Neu5Ac) in an a2–3 linkage [70]. This observation
suggests that Siglec-1 may serve as a pathogen recognition
receptor [65]. Lipidomic analyses of viral membranes revealed
the presence of sialylated gangliosides in retroviruses, including
HIV-1 and murine leukemia virus (MLV), and in vesicular
stomatitis virus and Semliki forest virus [58,73,75]. MLV is also
efficiently captured by mDCs via Siglec-1 [58,67]. Siglec-1 may
thus function as a general recognition receptor for many
enveloped viruses, leading to viral uptake into mDCs and the
induction of specific antiviral responses. Accordingly, Siglec-1-
expressing myeloid cells efficiently capture VSV in vivo, either
facilitating antiviral B cell responses or preventing viral neuroinva-
sion via type I interferon release [76,77].
Exclusion of sialyllactose-containing gangliosides from viral
budding domains or incorporation of neuraminidases that
Figure 3. HIV-1 and exosome targeting to Siglec-1. A. HIV-1 binds to Siglec-1 through viral membrane gangliosides. Viral capture is followed
by accumulation in a storage compartment until virus is released to infect a contacting CD4+ T cell via viral envelope glycoprotein and CD4/
coreceptor interactions. B. Exosomes bearing processed antigens on MHC II molecules bind to Siglec-1 through recognition of their membrane
gangliosides. They accumulate in the same storage compartment as HIV-1 until they are released and recognized by a CD4+ T cell via the interaction
of the antigen-loaded MHC II on the exosome with an antigen-specific T-cell receptor on the target cell.
doi:10.1371/journal.ppat.1004146.g003
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desialylate viral membrane glycolipids could interfere with mDC
capture and immune recognition. Influenza virus is largely devoid
of GM3 due to the viral neuraminidase [78], and it will be
interesting to determine whether this feature is important for
escape from immune recognition. HIV-1, on the other hand,
appears to subvert this cellular recognition pathway for its own
benefit. Indeed, enhanced HIV-1 capture by mDCs does not
correlate with better viral antigen presentation ability; iDCs are
capable of inducing higher antigen-specific T cell responses than
mDCs [79].
Sialic acid is also present on the surface of several medically
relevant nonviral human pathogens such as Neisseria meningiti-
dis, Haemophilus influenzae, group B Streptococcus, Campylobacter
jejuni, and several strains of Escherichia coli, as reviewed in [65].
These pathogens carry a lipopolysaccharide on their surface
with an external moiety that is similar to the sugar moiety in
human gangliosides [80]. Conceivably, these sialylated sugars
may be recognized by mDCs and lead to pathogen capture and
subsequent immune clearance. Recently, Siglec-1 has been
shown to mediate uptake of sialylated C. jejuni in macrophages,
promoting rapid proinflammatory cytokine secretion and type
I interferon responses [81]. It will thus be interesting to
determine whether these pathogens are also captured by mDCs
via Siglec-1. Although mDCs markedly down-regulate their
capacity for macropinocytosis, they are still able to capture,
process, and present antigens internalized via endocytic
receptors, suggesting that they may continuously initiate
responses to newly encountered antigens during the course of
infection [82,83]. mDC capture of particles with ganglioside-
containing membranes via Siglec-1 may have evolved as a
mechanism for recognition of sialylated pathogens, and
HIV-1 may have subverted this pathway for efficient viral
spread.
The role of Siglec-1 in immune surveillance is further
underscored by its ability to capture secreted exosomes and other
microvesicles [66,84], which are enriched in gangliosides [85].
Although their role in vivo is still controversial, exosomes are
capable of transferring antigens to other target cells and thus could
effectively increase the number of antigen-presenting cells (APCs)
presenting a particular epitope at a given time, amplifying immune
responses [86,87]. Thus, exosome targeting to Siglec-1 on the
surface of mDCs could favor specific triggering of immune
responses by specialized APCs.
Intriguingly, captured exosomes do not need to be fully
reprocessed and can induce immunity by direct release from
mDCs, following a similar pathway as HIV-1 during trans-infection
(Figure 3A). This occurs when captured exosomes expose
previously processed functional epitope–MHC complexes on their
surface that can be recognized by antigen-specific CD4+ T cells
(Figure 3B) [88]. Hence, beyond its function as a recognition
receptor for sialylated pathogens, the ability of Siglec-1 to capture
exosomes could reflect a wider role of this molecule in amplifying
immune responses.
Siglec-1 in HIV-1 Pathogenesis
Upon HIV-1 exposure, human genital mucosal epithelial cells
produce thymic stromal lymphopoietin (TSL) (Figure 4A), a
secreted factor leading to maturation of DCs that also triggers DC-
mediated amplification of HIV-1 infection in activated CD4+ T
cells [89]. It will thus be important to address whether Siglec-1
mediates HIV-1 entry into these DCs or into vaginal Langerhans
cells, where endocytosis of intact virions occurs primarily through
a pathway independent of C-type lectin receptors [90]. Mucosal
inflammation due to prior infection with other viruses, bacteria, or
fungi can also stimulate the maturation of resident or incoming
DCs by direct interaction with the invading pathogen or by
secreted inflammatory cytokines and chemokines, favoring trans-
infection events at early stages of HIV-1 invasion. This mechanism
could partially explain why prior and concomitant sexually
transmitted infections represent one of the strongest correlates of
HIV-1 acquisition [91] and why blocking immune activation can
protect animal models from mucosal simian immunodeficiency
virus (SIV) transmission [92].
Chronic systemic immune activation is a hallmark of progressive
HIV-1 infection, and various proinflammatory factors may induce
Siglec-1 expression and contribute to HIV-1 trans-infection. This is
the case for LPS, which is significantly augmented in chronically
HIV-1-infected individuals, due to increased translocation of
bacteria from the intestinal lumen [93]. The bacterial components
may stimulate DCs systemically (Figure 4B), contributing to their
maturation and therefore enhancing viral spread, while creating
the proinflammatory milieu associated with chronic HIV-1
infection.
Interferon alpha (IFNa) is a potent antiviral cytokine produced
by plasmacytoid DCs in response to HIV-1 challenge [94] that is
also able to induce Siglec-1 expression in myeloid cells, such as
DCs or monocytes [67,69]. Thus, besides its antiviral function,
IFNa can also favor HIV-1 trans-infection in an otherwise antiviral
environment [67,69]. Siglec-1 is up-regulated early after SIV
infection in both monocytes from pathogenic and nonpathogenic
animal SIV models, but its expression is only maintained in the
pathogenic model [95]. Higher HIV-1 viral load in humans
correlates with up-regulation of the Siglec-1 gene in circulating
monocytes [96]. This could be orchestrated by plasmacytoid DCs
(Figure 4C), which produce IFNa upon HIV-1 exposure and
induce the maturation of bystander DCs [97].
Concluding Remarks
Despite intensive research, there is uncertainty regarding the
role of DCs in the establishment of HIV-1 infection in vivo. The
field also lacks direct proof of DC participation in disease
progression. The discovery of the role of Siglec-1 in capturing
viruses with gangliosides in their membrane expands our
understanding of HIV-1 transmission mechanisms and offers a
new avenue to dissect the contribution of DCs to HIV-1
pathogenesis. In turn, this knowledge will help to design novel
therapeutic approaches aimed to prevent viral dissemination.
Figure 4. Immune activating signals can induce Siglec-1 expression and contribute to HIV-1 trans-infection. A. Human genital mucosal
epithelial cells produce TSL in response to HIV-1. This cytokine could induce maturation of Langerhans cells or dermal DCs in the mucosa. B.
Increased translocation of bacteria from the intestinal lumen after HIV-1 infection augments LPS levels that can stimulate DCs systemically. C. HIV-1-
infected plasmacytoid DCs produce interferon a in lymphoid tissues, which triggers maturation of bystander DCs and induces Siglec-1 expression.
Abbreviations: LC (Langerhans cells), pDC (plasmacytoid DC) TLR (toll-like receptor), TSL (thymic stromal lymphopoietin).
doi:10.1371/journal.ppat.1004146.g004
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